Abstract

BackgroundMitochondrial dysfunction has been suggested to play an important role in all stages of multiple sclerosis (MS).ObjectiveTo determine the expression of two mitophagy-related proteins, PTEN-induced kinase 1 (PINK1) and PARKIN, in a cohort of Japanese patients with different neuroinflammatory disorders.MethodsProtein concentrations were measured using commercial ELISA in paired cerebrospinal fluid (CSF) and serum samples from patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody disorders (MOGAD), and from age- and sex-matched controls.ResultsCSF and serum concentrations of PINK1 were higher in patients with MS than in patients with NMOSD (p = 0.004 and p < 0.001, respectively), MOGAD (p = 0.008 and p = 0.011, respectively), and controls (p = 0.021 and p = 0.002, respectively). CSF and concentrations of PARKIN were elevated in patients with MS in comparison with those in controls (p = 0.016 and p = 0.05, respectively).ConclusionsOur study highlighted the importance of mitophagy in MS and suggested the potential application of PINK1 and PARKIN as biomarkers to predict disease activity.

Highlights

  • Multiple sclerosis (MS) is a T cell-mediated disease of the central nervous system (CNS) primarily characterized by neuroinflammation [1]

  • cerebrospinal fluid (CSF) and serum concentrations of PTENinduced kinase 1 (PINK1) were higher in patients with multiple sclerosis (MS) than in patients with neuromyelitis optica spectrum disorders (NMOSD) (p = 0.004 and p < 0.001, respectively), myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) (p = 0.008 and p = 0.011, respectively), and controls (p = 0.021 and p = 0.002, respectively)

  • Considering the heterogeneity in the clinical course of patients with neuroinflammatory and neurodegenerative diseases, we investigated the presence of the specific mitophagy markers, PINK1 and PARKIN, in the bodily fluids of Japanese patients with MS, NMOSD and myelin oligodendrocyte glycoprotein antibody disorders (MOGAD)

Read more

Summary

Methods

Protein concentrations were measured using commercial ELISA in paired cerebrospinal fluid (CSF) and serum samples from patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody disorders (MOGAD), and from age- and sex-matched controls

Results
Conclusions
INTRODUCTION
METHOD
RESULTS
DISCUSSION
ETHICS STATEMENT
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call